Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2018 May 31

PMID 29843236

Citations 5

Authors

Stephanie L Adams

Laurent Benayoun

Kathy Tilton

Tiffany J Mellott

Sudha Seshadri

Jan Krzysztof Blusztajn

Ivana Delalle

Affiliations

Soon will be listed here.

Abstract

The pathophysiology of Alzheimer's disease (AD) includes signaling defects mediated by the transforming growth factor β-bone morphogenetic protein-growth and differentiation factor (TGFβ-BMP-GDF) family of proteins. In animal models of AD, administration of BMP9/GDF2 improves memory and reduces amyloidosis. The best characterized type I receptor of BMP9 is ALK1. We characterized ALK1 expression in the hippocampus using immunohistochemistry. In the rat, ALK1 immunoreactivity was found in CA pyramidal neurons, most frequently and robustly in the CA2 and CA3 fields. In addition, there were sporadic ALK1-immunoreactive cells in the stratum oriens, mainly in CA1. The ALK1 expression pattern in human hippocampus was similar to that of rat. Pyramidal neurons within the CA2, CA3, and CA4 were strongly ALK1-immunoreactive in hippocampi of cognitively intact subjects with no neurofibrillary tangles. ALK1 signal was found in the axons of alveus and fimbria, and in the neuropil across CA fields. Relatively strongest ALK1 neuropil signal was observed in CA1 where pyramidal neurons were occasionally ALK1-immunoractive. As in the rat, horizontally oriented neurons in the stratum oriens of CA1 were both ALK1- and GAD67-immunoreactive. Analysis of ALK1 immunoreactivity across stages of AD pathology revealed that disease progression was characterized by overall reduction of the ALK1 signal in CA3 in advanced, but not early, stages of AD. These data suggest that the CA3 pyramidal neurons may remain responsive to the ALK1 ligands, e.g., BMP9, during initial stages of AD and that ALK1 may constitute a therapeutic target in early and moderate AD.

Citing Articles

Effect of JM-20 on Age-Related Cognitive Impairment in Mice.

Wong-Guerra M, Montano-Peguero Y, Ramirez-Sanchez J, Alfonso E, Hernandez-Ensenat D, Isaac Y Neurochem Res. 2024; 50(1):8.

PMID: 39546064 DOI: 10.1007/s11064-024-04254-1.

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD.

Masuda H, Mori M, Uzawa A, Uchida T, Muto M, Ohtani R Sci Rep. 2023; 13(1):3538.

PMID: 36864239 PMC: 9981699. DOI: 10.1038/s41598-023-30594-z.

Peptides Derived from Growth Factors to Treat Alzheimer's Disease.

Gascon S, Jann J, Langlois-Blais C, Plourde M, Lavoie C, Faucheux N Int J Mol Sci. 2021; 22(11).

PMID: 34199883 PMC: 8200100. DOI: 10.3390/ijms22116071.

The Expression of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) in Hippocampal Arterioles Declines During Progression of Alzheimer's Disease.

Anderson K, Bellio T, Aniskovich E, Adams S, Blusztajn J, Delalle I Cereb Cortex Commun. 2020; 1(1):tgaa031.

PMID: 32974611 PMC: 7497413. DOI: 10.1093/texcom/tgaa031.

Analysis of gene expression profiling of amyloidogenic immunoglobulin light-chains on cultured rat cardiomyocytes.

Xu F, Yu Y, Wang F, Sun W, Li P, Wu H Exp Ther Med. 2020; 19(6):3767-3777.

PMID: 32346441 PMC: 7185198. DOI: 10.3892/etm.2020.8610.

References

Naj A, Jun G, Beecham G, Wang L, Vardarajan B, Buros J . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5):436-41. PMC: 3090745. DOI: 10.1038/ng.801. View

David L, Mallet C, Mazerbourg S, Feige J, Bailly S . Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2006; 109(5):1953-61. DOI: 10.1182/blood-2006-07-034124. View

Blessed G, Tomlinson B, Roth M . The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968; 114(512):797-811. DOI: 10.1192/bjp.114.512.797. View

Mufson E, Counts S, Perez S, Ginsberg S . Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother. 2008; 8(11):1703-18. PMC: 2631573. DOI: 10.1586/14737175.8.11.1703. View

Brown M, Zhao Q, Baker K, Naik C, Chen C, Pukac L . Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem. 2005; 280(26):25111-8. DOI: 10.1074/jbc.M503328200. View

DAVIS P, White H, Price J, McKeel D, ROBINS L . Retrospective postmortem dementia assessment. Validation of a new clinical interview to assist neuropathologic study. Arch Neurol. 1991; 48(6):613-7. DOI: 10.1001/archneur.1991.00530180069019. View

Adams S, Tilton K, Kozubek J, Seshadri S, Delalle I . Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral Cortex During the Progression of Alzheimer Disease Pathology. J Neuropathol Exp Neurol. 2016; 75(8):779-790. PMC: 6281026. DOI: 10.1093/jnen/nlw056. View

Podtelezhnikov A, Tanis K, Nebozhyn M, Ray W, Stone D, Loboda A . Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging. PLoS One. 2012; 6(12):e29610. PMC: 3247273. DOI: 10.1371/journal.pone.0029610. View

Lace G, Savva G, Forster G, De Silva R, Brayne C, Matthews F . Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain. 2009; 132(Pt 5):1324-34. DOI: 10.1093/brain/awp059. View

10.

Nykjaer Nikolajsen G, Jensen M, West M . Cholinergic axon length reduced by 300 meters in the brain of an Alzheimer mouse model. Neurobiol Aging. 2011; 32(11):1927-31. DOI: 10.1016/j.neurobiolaging.2011.05.006. View

11.

Townson S, Martinez-Hackert E, Greppi C, Lowden P, Sako D, Liu J . Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem. 2012; 287(33):27313-25. PMC: 3431715. DOI: 10.1074/jbc.M112.377960. View

12.

Machova E, Rudajev V, Smyckova H, Koivisto H, Tanila H, Dolezal V . Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice. Neurobiol Dis. 2010; 38(1):27-35. DOI: 10.1016/j.nbd.2009.12.023. View

13.

Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

14.

Hibar D, Adams H, Jahanshad N, Chauhan G, Stein J, Hofer E . Novel genetic loci associated with hippocampal volume. Nat Commun. 2017; 8:13624. PMC: 5253632. DOI: 10.1038/ncomms13624. View

15.

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

16.

Gratacos E, Gavalda N, Alberch J . Bone morphogenetic protein-6 is a neurotrophic factor for calbindin-positive striatal neurons. J Neurosci Res. 2002; 70(5):638-44. DOI: 10.1002/jnr.10438. View

17.

Hattori A, Katayama M, Iwasaki S, Ishii K, Tsujimoto M, Kohno M . Bone morphogenetic protein-2 promotes survival and differentiation of striatal GABAergic neurons in the absence of glial cell proliferation. J Neurochem. 1999; 72(6):2264-71. DOI: 10.1046/j.1471-4159.1999.0722264.x. View

18.

Bissonnette C, Lyass L, Bhattacharyya B, Belmadani A, Miller R, Kessler J . The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. Stem Cells. 2011; 29(5):802-11. PMC: 3107131. DOI: 10.1002/stem.626. View

19.

Fukutani Y, Cairns N, Shiozawa M, Sasaki K, Sudo S, Isaki K . Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late-onset sporadic Alzheimer's disease. Psychiatry Clin Neurosci. 2000; 54(5):523-9. DOI: 10.1046/j.1440-1819.2000.00747.x. View

20.

Sarter M, Bruno J . Developmental origins of the age-related decline in cortical cholinergic function and associated cognitive abilities. Neurobiol Aging. 2004; 25(9):1127-39. DOI: 10.1016/j.neurobiolaging.2003.11.011. View